NCI ETCTN Pittsburgh Cancer Consortium (PCC)

摘要 40多年来，美国国家癌症研究所（NCI）一直在支持一个基础设施， 计划在美国各地进行临床试验。加强、促进和加快这一进程 在药物开发的早期阶段，NCI实施了一项全面的计划， NCI赞助的早期临床试验计划由一系列独立的机构和努力 一个新的，统一的，综合的计划，被称为NCI实验治疗学 临床试验网络（ETCTN）。UPMC希尔曼癌症中心（前身为密歇根大学） 匹兹堡癌症研究所，以下简称“HCC”）已被指定为NCI 自1990年以来，他一直参与NCI早期药物治疗， 1999年以来的发展计划。我们的小组是12个学术中心之一，被选为 ETCTN领导学术组织（LAO），用于第1阶段的组成部分，随后 被选为整合2期临床试验工作的10个学术中心之一，负责 开发，领导和积累成人癌症患者的ETCTN临床试验。我们现在 我建议成为NCI ETCTN的成员，担任匹兹堡癌症联盟（PCC）的领导者 与佛罗里达大学健康癌症中心联合的学术组织， 爱因斯坦癌症中心PCC的目标是建立一个统一的，综合的临床 试验网络，将允许更无缝的进步和进展的新的实验 药剂和/或组合通过药物开发的早期阶段。我们的最终目标是 该计划将大大促进和加速向公民提供新的癌症治疗方法 宾夕法尼亚州、佛罗里达中北部、纽约州布朗克斯及其各自的集水区。

Abstract For more than 40 years, the National Cancer Institute (NCI) has supported an infrastructure program to conduct clinical trials across the US. To enhance, facilitate, and expedite the process of early-phase drug development, the NCI implemented a comprehensive plan transforming the NCI-sponsored early-phase clinical trials program from a series of separate institutions and efforts to a new, consolidated, integrated program, referred to as the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). The UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute, hereafter referred to as ‘HCC’) has been an NCI-designated comprehensive cancer center since 1990, and has been involved in the NCI Early Drug Development Program since 1999. Our group was one of 12 academic centers to be selected as an ETCTN Lead Academic Organization (LAO) for the phase 1 component, and subsequently selected as one of 10 academic centers to integrate phase 2 clinical trial efforts, with responsibility for developing, leading, and accruing to ETCTN clinical trials for adult cancer patients. We now propose to be a member of the NCI ETCTN as the Pittsburgh Cancer Consortium (PCC) Lead Academic Organization in a consortium with the University of Florida Health Cancer Center and the Albert Einstein Cancer Center. The goal of the PCC is to create a unified, integrated clinical trials network that will allow for more seamless advancement and progress of novel experimental agents and/or combinations through early stages of drug development. The eventual goal of our program is to greatly facilitate and accelerate the delivery of new cancer therapies to the citizens of Pennsylvania, North-Central Florida, Bronx, NY, and their respective catchment areas.